University of California, Irvine, Beckman Laser Institute, Irvine, California 92612, USA.
J Biomed Opt. 2011 Nov;16(11):116019. doi: 10.1117/1.3652711.
We previously developed a self-referencing differential spectroscopic (SRDS) method to detect lesions by identifying a spectroscopic biomarker of breast cancer, i.e., the specific tumor component (STC). The SRDS method is based on the assumption of the exclusive presence of this spectroscopic biomaker in malignant disease. Although clinical results using this method have already been published, the dependence of the STC spectra on the choice of reference tissue has not yet been addressed. In this study, we explore the impact of the selection of the reference region size and location on the STC spectrum in 10 subjects with malignant breast tumors. Referencing from both contralateral and ipsilateral sides was performed. Regardless of the referencing, we are able to obtain consistent high contrast images of malignant lesions using the STC with less than 13% deviation. These results suggest that the STC measurements are independent of any type, location, and amount of normal breast tissue used for referencing. This confirms the initial assumption of the SRDS analysis, that there are specific tumor components in cancer that do not exist in normal tissue. This also indicates that bilateral measurements are not required for lesion identification using the STC method.
我们之前开发了一种自参考差示光谱（SRDS）方法，通过识别乳腺癌的光谱生物标志物，即特定肿瘤成分（STC）来检测病变。SRDS 方法基于恶性疾病中仅存在这种光谱生物标志物的假设。尽管已经发表了使用该方法的临床结果，但 STC 光谱对参考组织选择的依赖性尚未得到解决。在这项研究中，我们探索了在 10 名患有恶性乳腺肿瘤的患者中，参考区域大小和位置的选择对 STC 光谱的影响。对双侧和同侧进行了参考。无论参考情况如何，我们都能够使用 STC 获得恶性病变的高对比度图像，偏差小于 13%。这些结果表明，STC 测量与用于参考的任何类型、位置和数量的正常乳腺组织无关。这证实了 SRDS 分析的最初假设，即癌症中存在不存在于正常组织中的特定肿瘤成分。这也表明，使用 STC 方法进行病变识别不需要双侧测量。
